Travere Therapeutics (TVTX) Revenue (2014 - 2026)

Travere Therapeutics' Revenue history runs 13 years deep, the most recent figure standing at $127.2 million for Q1 2026.

• Quarterly Revenue rose 55.63% year-over-year to $127.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70.1 million (down 125.62% YoY) and the FY2025 annual result came in at $9.3 million, down 96.01% from the prior year.
• Revenue was $127.2 million for Q1 2026 at Travere Therapeutics, up from -$351.7 million in the prior quarter.
• Across five years, Revenue topped out at $127.2 million in Q1 2026 and bottomed at -$351.7 million in Q4 2025.
• A 5-year average of $29.4 million and a median of $40.0 million in 2025 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue soared 118.54% — and 2025, when it sank 570.32%.
• Travere Therapeutics' Revenue stood at $29.3 million in 2022, then soared by 53.58% to $45.1 million in 2023, then jumped by 65.98% to $74.8 million in 2024, then sank by 570.32% to -$351.7 million in 2025, then jumped by 136.16% to $127.2 million in 2026.
• Business Quant data shows TVTX's Revenue at $127.2 million in Q1 2026, -$351.7 million in Q4 2025, and $40.0 million in Q3 2025.